Samsung and Biogen Idec have entered an agreement to invest $300 million to establish a joint venture for the development, manufacture, and commercialization of biosimilars. Samsung will contribute $255 million for an 85% stake and Biogen Idec will contribute $45 million for a 15% stake. The joint venture, which will be based in Korea, will contract Biogen Idec and Samsung Biologics for technical development and manufacturing services. The joint venture will not pursue biosimilars of Biogen’s pr...